Recent News

• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
• 09.09.2025 - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
• 09.03.2025 - Cantor Global Healthcare Conference
• 08.27.2025 - Aclaris Therapeutics to Participate in Two September Healthcare Conferences
• 08.27.2025 - Aclaris Therapeutics to Participate in Two September Healthcare Conferences
• 08.07.2025 - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.07.2025 - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 07.29.2025 - Aclaris Therapeutics ATI-2138 Phase 2a Results and ITK Franchise Update
• 07.29.2025 - Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Recent Filings

• 08.07.2025 - 8-K Current report
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2025 - 3 Initial statement of beneficial ownership of securities
• 07.29.2025 - EX-99.1 EX-99.1
• 07.29.2025 - 8-K Current report
• 07.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors